Hong Kong Stock Movement: BIOSINO BIO-TEC rose by 15.81%, with clear capital flow, market sentiment triggered volatility attention

Hong Kong Stock Market Movements BIOSINO BIO-TEC rose by 15.81%, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry Sihuan Pharmaceutical fell by 4.02%. Based on recent news, On January 23, Sanfu Pharma announced that its subsidiary Sanfu Biomedical has initiated an IPO plan and completed a cash increase of over 300 million yuan. This move may attract market attention towards Sihuan Pharmaceutical, leading to stock price fluctuations. Sanfu Biomedical focuses on new drug development in the fields of cancer, autoimmune diseases, and ophthalmic diseases, attracting investor interest. No other significant news recently. The Hong Kong stock market has been quite volatile lately and requires attention. CanSino Biologics fell by 4.12%, with a trading volume of HKD 628 million, and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Innovent Biologics fell by 2.63%. Based on recent key news: On January 23, a large number of Innovent's products entered the medical insurance system, enhancing market trust and brand influence, but profit margins were compressed, and the profit structure faced reconstruction, leading to stock price fluctuations. Source: Zhitong Finance On December 26, Novo Nordisk's semaglutide price was reduced, with a maximum drop of nearly 50%, and Eli Lilly's tirzepatide price plummeted, intensifying market competition, putting Innovent in a difficult position. Source: Zhitong Finance On January 16, the Anhui Provincial Medical Security Conference announced a centralized procurement for biological drugs, causing Innovent's stock price to plummet in the afternoon, with a maximum drop of over 14%. Source: Zhitong Finance. The competition in the biological drug market has intensified, increasing risks. Stocks with High Market Capitalization in the Industry BeiGene fell by 1.27%, with a market capitalization of HKD 310.6 billion, and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation